lpca Laboratories inks tech transfer deal with Omexa Formulary

lpca Laboratories Ltd’s shares were up by 0.78 per cent after the company finalised a technology transfer agreement with Omexa Formulary Pvt Ltd, aimed at biosimilar development for the global market. lpca will grant Omexa a non-exclusive right to research, develop, manufacture, and market an anti-cancer biosimilar globally.

The company said the collaboration empowers Omexa to progress from the early stages of biosimilar development to clinical trials and eventual commercial launch.

Pranay Godha, Managing Director and CEO of lpca Laboratories, said, “This collaboration with Omexa Formulary, an innovation-driven and fast-growing biotech company, shall facilitate Omexa to build a solid foundation for potential anti-cancer and anti-inflammatory monoclonal antibody product development… (and) the development and delivery of affordable and quality biologic medication for the treatment of chronic illnesses in the global market — a presently unmet and crucial clinical need. lpca is committed to successfully developing quality and affordable biosimilars, meeting global standards and gaining a decisive edge in the battle against chronic ailments.”

The shares were up by 0.78 per cent to ₹1,210.50 at 2.08 pm on the BSE.

Crime Today News | Markets | Commodities | Forex | Stocks

Source | Powered by Yes Mom Hosting
Crime Today News Agency

Crime Today News

Welcome to Crime Today News, your trusted source for timely and unbiased news coverage. Since our inception in 2014, we have been dedicated to delivering the latest updates to our valued readers and viewers across Telangana.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *